Biosyent Inc RX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CA$17.15
- Day Range
- CA$16.97–17.00
- 52-Week Range
- CA$10.65–17.50
- Bid/Ask
- CA$16.70 / CA$16.96
- Shares Outstanding
- 11.23M
- Market Cap
- CA$190.61M
- Volume/Avg
- 2,506 / 10,458
Key Statistics
- Price/Earnings (Normalized)
- 19.25
- Price/Sales
- 3.56
- Dividend Yield (Trailing)
- 1.25%
- Dividend Yield (Forward)
- 1.28%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 2.62%
Company Profile
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- http://www.biosyent.com
Valuation
|
Metric
|
RX
|
|---|---|
Price/Earnings (Normalized) | 19.25 |
Price/Book Value | 4.24 |
Price/Sales | 3.56 |
Price/Cash Flow | 16.62 |
Price/Earnings
RX
Financial Strength
|
Metric
|
RX
|
|---|---|
Quick Ratio | 1.14 |
Current Ratio | 2.07 |
Interest Coverage | 120.16 |
Quick Ratio
RX
Profitability
|
Metric
|
RX
|
|---|---|
Return on Assets (Normalized) | 20.32% |
Return on Equity (Normalized) | 25.53% |
Return on Invested Capital (Normalized) | 23.29% |
Return on Assets
RX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|!&zQpW! | LOCK|vNdm | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|n!C@Zl@S | LOCK|Dk%J! | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|!R<F$&Q | LOCK|wC | $41B | |||
| Zoetis Inc Class A
ZTS
| LOCK|l>D>yW^g | LOCK|g% | $31B | |||
| Viatris Inc
VTRS
| LOCK|$mP^v& | LOCK|!m# | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|P?y | LOCK|q#! | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|d%<%%$ | LOCK|<J | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|#&g>L$y | LOCK|DQ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|&B&%#!c | LOCK|CvsW | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|y&CT!? | LOCK|bk | $2B |
United States